Alecensa and Alunbrig Comparison

Alecensa®(alectinib)	Alunbrig®(brigatinib)
Prescription Only Alecensa is a medication that belongs to the class of tyrosine kinase inhibitors and can be used to treat non-small cell lung cancer (NSCLC) caused by a mutation in the ALK gene....	Prescription Only Alunbrig is a cancer medication that stops the growth and spread of cancer cells. It is prescribed for treating metastatic non-small cell lung cancer in patients whose cancer has...
Administration
Oral with food. Learn more.	Oral . Learn more.
Dosing
600 mg twice daily. Learn more.	90 mg for first 7 days, then increase to 180 mg once daily, may be taken with or without food. Learn more.
Latin Shorthand
600mg BID. Learn more.	90 mg x7d, then 180 mg po qd (with/without food). Learn more.
Out-Of-Pocket Costs With Copay Card
$5. Learn more.	$0. Learn more.
Annual Cap
$25,000. Learn more.	Learn more.
Assistance Expiration
Learn more.	12 months. Learn more.
Generics
No lower-cost generic available	No lower-cost generic available
Adverse Reactions
The most common adverse reactions (incidence ≥20%) were fatigue, constipation, edema, myalgia, and anemia.. Learn more.	The most common adverse reactions (≥25%) with ALUNBRIG were diarrhea, fatigue, nausea, rash, cough, myalgia, headache, hypertension, vomiting, and dyspnea.. Learn more.
Mechanism of Actions (MoA)
Kinase inhibitors. Learn more.	Tyrosine kinase inhibitors; Cytochrome P450 3A inducers. Learn more.
Special Populations
Can ALECENSA be used during pregnancy? No, ALECENSA can cause fetal harm when administered to a pregnant woman. It is advised to avoid using ALECENSA during pregnancy and advise pregnant women of the potential risk to a fetus. Can ALECENSA be used during lactation? No, there are no data on the presence of alectinib or its metabolites in human milk, the effects of alectinib on the breastfed infant, or its effects on milk production. It is advised to not breastfeed during treatment with ALECENSA and for 1 week after the final dose. Should females and males of reproductive potential use contraception during treatment with ALECENSA? Yes, females of reproductive potential should use effective contraception during treatment with ALECENSA and for 1 week after the final dose. Males with female partners of reproductive potential should also use effective contraception during treatment with ALECENSA and for 3 months following the final dose. Is ALECENSA safe for pediatric use? The safety and effectiveness of ALECENSA in pediatric patients have not been established. Is ALECENSA safe for geriatric use? Clinical studies of ALECENSA did not include a sufficient number of subjects aged 65 and older to determine whether they respond differently from younger subjects. Is ALECENSA safe for use in patients with renal or hepatic impairment? No dose adjustment is recommended for patients with mild or moderate renal impairment or mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. However, the safety of ALECENSA in patients with severe renal impairment (creatinine clearance less than 30 mL/min) or end-stage renal disease and severe hepatic impairment (Child-Pugh C) is unknown.	What is the risk of taking ALUNBRIG during pregnancy? Based on its mechanism of action and findings in animals, ALUNBRIG can cause fetal harm when administered to a pregnant woman. There are no clinical data on the use of ALUNBRIG in pregnant women. Administration of brigatinib to pregnant rats during the period of organogenesis resulted in dose-related skeletal anomalies, increased post-implantation loss, malformations, and decreased fetal body weight. Advise pregnant women of the potential risk to a fetus. What is the estimated background risk of birth defects and miscarriage in pregnant women? In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Is it safe to take ALUNBRIG while breastfeeding? There are no data regarding the secretion of brigatinib in human milk or its effects on the breastfed infant or milk production. Because of the potential for adverse reactions in breastfed infants, advise lactating women not to breastfeed during treatment with ALUNBRIG and for 1 week following the final dose. What precautions should females and males of reproductive potential take while taking ALUNBRIG? Females of reproductive potential should verify pregnancy status prior to initiating ALUNBRIG and use effective contraception during treatment and for at least 4 months after the final dose. Males with female partners of reproductive potential should also use effective contraception during treatment and for at least 3 months after the final dose. ALUNBRIG may cause reduced fertility in males based on findings in animal studies. Is ALUNBRIG safe for use in pediatric patients? The safety and effectiveness of ALUNBRIG in pediatric patients have not been established. Is ALUNBRIG safe for use in geriatric patients? No overall differences in safety or effectiveness were observed between patients aged 65 years and older and younger patients in clinical studies. Are dose adjustments necessary for patients with hepatic or renal impairment? Reduce the dose of ALUNBRIG for patients with severe hepatic impairment (Child-Pugh C) and severe renal impairment (creatinine clearance 15 to 29 mL/min). No dose adjustment is recommended for patients with mild or moderate hepatic impairment (Child-Pugh A or B) or mild or moderate renal impairment (creatinine clearance 30 to 89 mL/min).

Alecensa®(alectinib)

Alunbrig®(brigatinib)

Prescription Only

Alecensa is a medication that belongs to the class of tyrosine kinase inhibitors and can be used to treat non-small cell lung cancer (NSCLC) caused by a mutation in the ALK gene....

Prescription Only

Alunbrig is a cancer medication that stops the growth and spread of cancer cells. It is prescribed for treating metastatic non-small cell lung cancer in patients whose cancer has...

Dosage & Administration

Administration

Oral with food. Learn more.

Oral . Learn more.

Dosing

600 mg twice daily. Learn more.

90 mg for first 7 days, then increase to 180 mg once daily, may be taken with or without food. Learn more.

Latin Shorthand

600mg BID. Learn more.

90 mg x7d, then 180 mg po qd (with/without food). Learn more.

Financial Assistance

Out-Of-Pocket Costs With Copay Card

$5. Learn more.

$0. Learn more.

Annual Cap

$25,000. Learn more.

Learn more.

Assistance Expiration

Learn more.

12 months. Learn more.

Generics

No lower-cost generic available

Physician Advisory

Adverse Reactions

The most common adverse reactions (incidence ≥20%) were fatigue, constipation, edema, myalgia, and anemia.. Learn more.

The most common adverse reactions (≥25%) with ALUNBRIG were diarrhea, fatigue, nausea, rash, cough, myalgia, headache, hypertension, vomiting, and dyspnea.. Learn more.

Mechanism of Actions (MoA)

Kinase inhibitors. Learn more.

Tyrosine kinase inhibitors; Cytochrome P450 3A inducers. Learn more.

Special Populations

Can ALECENSA be used during pregnancy?

No, ALECENSA can cause fetal harm when administered to a pregnant woman. It is advised to avoid using ALECENSA during pregnancy and advise pregnant women of the potential risk to a fetus.

Can ALECENSA be used during lactation?

No, there are no data on the presence of alectinib or its metabolites in human milk, the effects of alectinib on the breastfed infant, or its effects on milk production. It is advised to not breastfeed during treatment with ALECENSA and for 1 week after the final dose.

Should females and males of reproductive potential use contraception during treatment with ALECENSA?

Yes, females of reproductive potential should use effective contraception during treatment with ALECENSA and for 1 week after the final dose. Males with female partners of reproductive potential should also use effective contraception during treatment with ALECENSA and for 3 months following the final dose.

Is ALECENSA safe for pediatric use?

The safety and effectiveness of ALECENSA in pediatric patients have not been established.

Is ALECENSA safe for geriatric use?

Clinical studies of ALECENSA did not include a sufficient number of subjects aged 65 and older to determine whether they respond differently from younger subjects.

Is ALECENSA safe for use in patients with renal or hepatic impairment?

No dose adjustment is recommended for patients with mild or moderate renal impairment or mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. However, the safety of ALECENSA in patients with severe renal impairment (creatinine clearance less than 30 mL/min) or end-stage renal disease and severe hepatic impairment (Child-Pugh C) is unknown.

What is the risk of taking ALUNBRIG during pregnancy?

Based on its mechanism of action and findings in animals, ALUNBRIG can cause fetal harm when administered to a pregnant woman. There are no clinical data on the use of ALUNBRIG in pregnant women. Administration of brigatinib to pregnant rats during the period of organogenesis resulted in dose-related skeletal anomalies, increased post-implantation loss, malformations, and decreased fetal body weight. Advise pregnant women of the potential risk to a fetus.

What is the estimated background risk of birth defects and miscarriage in pregnant women?

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Is it safe to take ALUNBRIG while breastfeeding?

There are no data regarding the secretion of brigatinib in human milk or its effects on the breastfed infant or milk production. Because of the potential for adverse reactions in breastfed infants, advise lactating women not to breastfeed during treatment with ALUNBRIG and for 1 week following the final dose.

What precautions should females and males of reproductive potential take while taking ALUNBRIG?

Females of reproductive potential should verify pregnancy status prior to initiating ALUNBRIG and use effective contraception during treatment and for at least 4 months after the final dose. Males with female partners of reproductive potential should also use effective contraception during treatment and for at least 3 months after the final dose. ALUNBRIG may cause reduced fertility in males based on findings in animal studies.

Is ALUNBRIG safe for use in pediatric patients?

The safety and effectiveness of ALUNBRIG in pediatric patients have not been established.

Is ALUNBRIG safe for use in geriatric patients?

No overall differences in safety or effectiveness were observed between patients aged 65 years and older and younger patients in clinical studies.

Are dose adjustments necessary for patients with hepatic or renal impairment?

Reduce the dose of ALUNBRIG for patients with severe hepatic impairment (Child-Pugh C) and severe renal impairment (creatinine clearance 15 to 29 mL/min). No dose adjustment is recommended for patients with mild or moderate hepatic impairment (Child-Pugh A or B) or mild or moderate renal impairment (creatinine clearance 30 to 89 mL/min).

Alecensa® Alternatives